Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden.

PubWeight™: 4.95‹?› | Rank: Top 1%

🔗 View Article (PMID 17296822)

Published in N Engl J Med on February 12, 2007


Bo Lagerqvist1, Stefan K James, Ulf Stenestrand, Johan Lindbäck, Tage Nilsson, Lars Wallentin, SCAAR Study Group

Author Affiliations

1: Uppsala Clinical Research Center, Uppsala University Hospital, Uppsala, Sweden. bo.lagerqvist@ucr.uu.se

Articles citing this

(truncated to the top 100)

A comparison of bare-metal and drug-eluting stents for off-label indications. N Engl J Med (2008) 2.60

Outcomes following coronary stenting in the era of bare-metal vs the era of drug-eluting stents. JAMA (2008) 2.47

Long-term survival and repeat coronary revascularization in dialysis patients after surgical and percutaneous coronary revascularization with drug-eluting and bare metal stents in the United States. Circulation (2013) 2.47

Unanswered questions--drug-eluting stents and the risk of late thrombosis. N Engl J Med (2007) 1.70

Long-term clinical outcomes after drug-eluting and bare-metal stenting in Massachusetts. Circulation (2008) 1.68

Assessing the cost effectiveness of using prognostic biomarkers with decision models: case study in prioritising patients waiting for coronary artery surgery. BMJ (2010) 1.65

Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis. BMJ (2013) 1.57

Clinical effectiveness of coronary stents in elderly persons: results from 262,700 Medicare patients in the American College of Cardiology-National Cardiovascular Data Registry. J Am Coll Cardiol (2009) 1.55

Human autopsy study of drug-eluting stents restenosis: histomorphological predictors and neointimal characteristics. Eur Heart J (2013) 1.54

A randomized, prospective, intercontinental evaluation of a bioresorbable polymer sirolimus-eluting coronary stent system: the CENTURY II (Clinical Evaluation of New Terumo Drug-Eluting Coronary Stent System in the Treatment of Patients with Coronary Artery Disease) trial. Eur Heart J (2014) 1.46

Drug-Eluting Versus Bare-Metal Stents During PCI in Patients With End-Stage Renal Disease on Dialysis. J Am Coll Cardiol (2016) 1.41

Survival advantage in Medicare patients receiving drug-eluting stents compared with bare metal stents: real or artefactual? Catheter Cardiovasc Interv (2008) 1.39

Safety of an abbreviated duration of dual antiplatelet therapy (≤6 months) following second-generation drug-eluting stents for coronary artery disease: A systematic review and meta-analysis of randomized trials. Catheter Cardiovasc Interv (2015) 1.39

Third generation drug eluting stent (DES) with biodegradable polymer in diabetic patients: 5 years follow-up. Cardiovasc Diabetol (2017) 1.39

Non thermal irreversible electroporation: novel technology for vascular smooth muscle cells ablation. PLoS One (2009) 1.29

Emerging applications of nanomedicine for the diagnosis and treatment of cardiovascular diseases. Trends Pharmacol Sci (2010) 1.22

Targeting stents with local delivery of paclitaxel-loaded magnetic nanoparticles using uniform fields. Proc Natl Acad Sci U S A (2010) 1.19

Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. Clin Res Cardiol (2008) 1.18

Improving medical device regulation: the United States and Europe in perspective. Milbank Q (2014) 1.13

Tissue coverage of a hydrophilic polymer-coated zotarolimus-eluting stent vs. a fluoropolymer-coated everolimus-eluting stent at 13-month follow-up: an optical coherence tomography substudy from the RESOLUTE All Comers trial. Eur Heart J (2011) 1.06

Lesion complexity determines arterial drug distribution after local drug delivery. J Control Release (2009) 1.00

Therapeutic innovations, diminishing returns, and control rate preservation. JAMA (2009) 1.00

Drug-eluting coronary stents--promise and uncertainty. N Engl J Med (2007) 0.99

Isopropylamine NONOate (IPA/NO) moderates neointimal hyperplasia following vascular injury. J Vasc Surg (2010) 0.97

Second- and third-generation drug-eluting coronary stents: progress and safety. Herz (2011) 0.93

Optical coherence tomography: from research to practice. Eur Heart J Cardiovasc Imaging (2012) 0.90

Potential shift from coronary bypass surgery to percutaneous coronary intervention for multivessel disease and its economic impact in the drug-eluting stent era. Can J Cardiol (2007) 0.90

Long-term outcomes of patients receiving drug-eluting stents. CMAJ (2008) 0.90

Benefit of long-term dual anti-platelet therapy in patients treated with drug-eluting stents: from the NHLBI dynamic registry. Am J Cardiol (2012) 0.90

Impact of diabetes on long-term outcome after primary angioplasty: insights from the DESERT cooperation. Diabetes Care (2012) 0.88

New concepts in the design of drug-eluting coronary stents. Nat Rev Cardiol (2013) 0.87

Complete versus incomplete revascularization for treatment of multivessel coronary artery disease in the drug-eluting stent era. Heart Vessels (2011) 0.86

Macro- and microscale variables regulate stent haemodynamics, fibrin deposition and thrombomodulin expression. J R Soc Interface (2014) 0.86

Clinical outcomes of different first- and second-generation drug-eluting stents in routine clinical practice: results from the prospective multicenter German DES.DE registry. Clin Res Cardiol (2013) 0.85

New horizons of acute myocardial infarction: from the Korea Acute Myocardial Infarction Registry. J Korean Med Sci (2013) 0.85

Anti-inflammatory effects of arsenic trioxide eluting stents in a porcine coronary model. Biomed Res Int (2013) 0.85

The effect of cilostazol on stent thrombosis after drug-eluting stent implantation. Korean Circ J (2010) 0.85

Emerging applications of nanotechnology for the diagnosis and management of vulnerable atherosclerotic plaques. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2011) 0.84

Drug-eluting stents. Int J Clin Exp Med (2010) 0.84

Second generation drug-eluting stents: a review of the everolimus-eluting platform. Clin Med Insights Cardiol (2013) 0.83

Clinical Trial Updates and Hotline Sessions presented at the European Society of Cardiology Congress 2007: (FINESSE, CARESS, OASIS 5, PRAGUE-8, OPTIMIST, GRACE, STEEPLE, SCAAR, STRATEGY, DANAMI-2, ExTRACT-TIMI-25, ISAR-REACT 2, ACUITY, ALOFT, 3CPO, PROSPECT, EVEREST, COACH, BENEFiT, MERLIN-TIMI 36, SEARCH-MI, ADVANCE, WENBIT, EUROASPIRE I-III, ARISE, getABI, RIO). Clin Res Cardiol (2007) 0.83

Long-term (≥2 years) follow-up optical coherence tomographic study after sirolimus- and paclitaxel-eluting stent implantation: comparison to 9-month follow-up results. Int J Cardiovasc Imaging (2010) 0.82

Smoking modifies the associated increased risk of future cardiovascular disease by genetic variation on chromosome 9p21. PLoS One (2014) 0.82

Reporting of harm in randomized controlled trials evaluating stents for percutaneous coronary intervention. Trials (2009) 0.82

Are drug-eluting stents safe in the long term? CMAJ (2008) 0.82

Late outcomes following percutaneous coronary interventions: results from a large, observational registry. Can J Cardiol (2010) 0.82

A first-in-man study of sirolimus-eluting, biodegradable polymer coated cobalt chromium stent in real life patients. Indian Heart J (2012) 0.81

Clinical outcomes of second- versus first-generation drug-eluting stents in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials. Arch Med Sci (2014) 0.81

Point-of-care platelet function assays demonstrate reduced responsiveness to clopidogrel, but not aspirin, in patients with Drug-Eluting Stent Thrombosis whilst on dual antiplatelet therapy. Thromb J (2008) 0.81

Acute coronary syndrome as a first presentation of systemic lupus erythematosus in a teenager: revascularization by hybrid coronary artery bypass graft surgery and percutaneous coronary intervention: case report. Pediatr Cardiol (2007) 0.81

Stent thrombosis in real-world patients: a comparison of drug-eluting with bare metal stents. Neth Heart J (2007) 0.81

Combination coating of chitosan and anti-CD34 antibody applied on sirolimus-eluting stents can promote endothelialization while reducing neointimal formation. BMC Cardiovasc Disord (2012) 0.81

Sympathetic nerve activity in stress-induced cardiomyopathy. Clin Auton Res (2012) 0.80

Comparison of the efficacy of drug-eluting stents versus bare-metal stents for the treatment of left main coronary artery disease. Chin Med J (Engl) (2015) 0.80

Comparison of outcome in 1809 patients treated with drug-eluting stents or bare-metal stents in a real-world setting. Vasc Health Risk Manag (2011) 0.80

Drug-eluting stents ameliorate pulmonary vein stenotic changes in pigs in vivo. Pediatr Cardiol (2010) 0.80

Targeting PI3Kγ activity decreases vascular trauma-induced intimal hyperplasia through modulation of the Th1 response. J Exp Med (2014) 0.80

My Interventional Drug-Eluting Stent Educational App (MyIDEA): Patient-Centered Design Methodology. JMIR Mhealth Uhealth (2015) 0.80

Clinical evidence of interaction between clopidogrel and proton pump inhibitors. World J Cardiol (2011) 0.79

Where does the Occluded Artery Trial leave the late open artery hypothesis? Heart (2007) 0.79

Long-term outcomes with paclitaxel-eluting stents versus bare metal stents in everyday practice: a Canadian experience. Can J Cardiol (2010) 0.79

Cystatin C Is Not Causally Related to Coronary Artery Disease. PLoS One (2015) 0.79

Drug-eluting stents or coronary artery bypass grafting for unprotected left main coronary artery disease: a meta-analysis of four randomized trials and seventeen observational studies. Trials (2013) 0.79

Comparative assessment of the antirestenotic efficacy of two paclitaxel drug-eluting balloons with different coatings in the treatment of in-stent restenosis. Clin Res Cardiol (2015) 0.79

Long-term outcome after drug-eluting stent implantation in comparison with bare metal stents: a single centre experience. Clin Res Cardiol (2010) 0.79

Percutaneous coronary intervention for unprotected left main coronary artery stenosis. World J Cardiol (2010) 0.78

Systematic Review of Chinese Herbal Medicines for Preventing in-Stent Coronary Restenosis after Percutaneous Coronary Intervention. Evid Based Complement Alternat Med (2012) 0.78

Selective versus exclusive use of drug-eluting stents in treating multivessel coronary artery disease: a real-world cohort study. Tex Heart Inst J (2014) 0.78

Short- and long-term outcomes of single bare metal stent versus drug eluting stent in nondiabetic patients with a simple de novo lesion in the middle and large vessel. J Transl Med (2008) 0.78

Comparison of Bare-Metal Stent and Drug-Eluting Stent for the Treatment of Patients Undergoing Percutaneous Coronary Intervention for Unprotected Left Main Coronary Artery Disease - Long-Term Result from a Single Center Experience. Zhonghua Minguo Xin Zang Xue Hui Za Zhi (2015) 0.78

Outcomes in patients with acute and stable coronary syndromes; insights from the prospective NOBORI-2 study. PLoS One (2014) 0.78

Duration of clopidogrel treatment and risk of mortality and recurrent myocardial infarction among 11 680 patients with myocardial infarction treated with percutaneous coronary intervention: a cohort study. BMC Cardiovasc Disord (2010) 0.78

Transanal hemorrhoidal dearterialization (THD): a safe procedure for the anticoagulated patient? Tech Coloproctol (2016) 0.78

In vitro endothelialization of cobalt chromium alloys with micro/nanostructures using adipose-derived stem cells. J Mater Sci Mater Med (2013) 0.77

In-vitro assessment of coronary artery stents in 256-multislice computed tomography angiography. BMC Res Notes (2014) 0.77

A randomized multicenter comparison of hybrid sirolimus-eluting stents with bioresorbable polymer versus everolimus-eluting stents with durable polymer in total coronary occlusion: rationale and design of the Primary Stenting of Occluded Native Coronary Arteries IV study. Trials (2012) 0.77

In-stent thrombosis after 68 months of implantation inspite of continuous dual antiplatelet therapy: a case report. Cases J (2010) 0.77

Advances in stent technologies and their effect on clinical efficacy and safety. Med Devices (Auckl) (2014) 0.77

The chromosome 9p21 variant interacts with vegetable and wine intake to influence the risk of cardiovascular disease: a population based cohort study. BMC Med Genet (2014) 0.77

Two-year results of an open-label randomized comparison of everolimus-eluting stents and sirolimus-eluting stents. PLoS One (2013) 0.77

Peroxisome proliferator-activated receptor-gamma agonists suppress tissue factor overexpression in rat balloon injury model with paclitaxel infusion. PLoS One (2011) 0.77

Titanium-nitride-oxIde-coated stents multicenter registry in diaBEtic patienTs: the TIBET registry. Heart Vessels (2011) 0.77

Resolution of late sirolimus-eluting stent thrombosis after tirofiban treatment. Heart Vessels (2009) 0.76

Impact of Anemia and Dual Antiplatelet Therapy on Mortality in Patients Undergoing Percutaneous Coronary Intervention with Drug-Eluting Stents. Sci Rep (2015) 0.76

Drug-eluting coronary stents - focus on improved patient outcomes. Patient Relat Outcome Meas (2011) 0.76

Estrogen-eluting stents. J Cardiovasc Transl Res (2009) 0.76

Magnetically targeted delivery of therapeutic agents to injured blood vessels for prevention of in-stent restenosis. Methodist Debakey Cardiovasc J (2012) 0.76

Accelerated Recovery of Endothelium Function after Stent Implantation with the Use of a Novel Systemic Nanoparticle Curcumin. Biomed Res Int (2015) 0.76

Very long-term follow-up of strut apposition and tissue coverage with Biolimus A9 stents analyzed by optical coherence tomography. Int J Cardiovasc Imaging (2013) 0.76

Stent strut coverage of titanium-nitride-oxide coated stent compared to paclitaxel-eluting stent in acute myocardial infarction: TITAX-OCT study. Int J Cardiovasc Imaging (2012) 0.75

Changes in the safety paradigm with percutaneous coronary interventions in the modern era: Lessons learned from the ASCERT registry. World J Cardiol (2012) 0.75

Abstract from the SCAAR registry. EuroIntervention (2008) 0.75

Clinical outcomes in 995 unselected real-world patients treated with an ultrathin biodegradable polymer-coated sirolimus-eluting stent: 12-month results from the FLEX Registry. BMJ Open (2016) 0.75

First human trial of KW39 slotted-tube stents: for percutaneous coronary intervention. Tex Heart Inst J (2011) 0.75

Antiplatelet therapy in acute coronary syndromes: current agents and impact on patient outcomes. Patient Relat Outcome Meas (2010) 0.75

Comparison of bare metal stent and paclitaxel-eluting stent using a novel rat aorta stent model. J Vet Sci (2011) 0.75

Sirolimus-eluting stents versus bare-metal stents in routine clinical use: a nonrandomized comparison. Tex Heart Inst J (2011) 0.75

Duration of dual antiplatelet therapy following percutaneous coronary intervention on re-hospitalization for acute coronary syndrome. BMC Cardiovasc Disord (2014) 0.75

Simultaneous very late stent thrombosis in multiple coronary arteries. Tex Heart Inst J (2012) 0.75

Reducing Neointima Formation in a Swine Model with IVUS and Sirolimus Microbubbles. Ann Biomed Eng (2015) 0.75

Articles by these authors

Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97

Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J (2012) 18.18

2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J (2013) 9.54

Thrombus aspiration during ST-segment elevation myocardial infarction. N Engl J Med (2013) 8.13

Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59

Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA (2005) 6.81

Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J (2007) 6.51

Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation (2011) 6.48

Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA (2006) 5.74

Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med (2006) 5.24

Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med (2011) 4.81

Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation (2012) 4.33

N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation (2003) 4.31

Association between adoption of evidence-based treatment and survival for patients with ST-elevation myocardial infarction. JAMA (2011) 3.90

Long-term outcome of primary percutaneous coronary intervention vs prehospital and in-hospital thrombolysis for patients with ST-elevation myocardial infarction. JAMA (2006) 3.79

Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation (2007) 3.62

The second Euro Heart Survey on acute coronary syndromes: Characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004. Eur Heart J (2006) 3.62

Newly identified events in the RE-LY trial. N Engl J Med (2010) 3.35

Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol (2010) 3.26

Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med (2011) 3.20

Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis. JAMA (2008) 3.12

Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J (2006) 3.10

Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation (2013) 3.02

Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke (2012) 3.02

5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study. Lancet (2006) 3.01

Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. N Engl J Med (2002) 3.01

Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet (2010) 2.98

Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J (2012) 2.94

Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet (2013) 2.92

Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med (2014) 2.90

N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol (2013) 2.90

A long-term perspective on the protective effects of an early invasive strategy in unstable coronary artery disease: two-year follow-up of the FRISC-II invasive study. J Am Coll Cardiol (2002) 2.87

New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. Eur Heart J (2013) 2.81

Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy. Circulation (2012) 2.74

Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation (2013) 2.72

Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. Eur Heart J (2009) 2.68

The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation (2013) 2.64

Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J (2009) 2.61

Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke (2013) 2.52

Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study. Circulation (2013) 2.48

Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. Ann Intern Med (2011) 2.45

New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol (2012) 2.41

N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease. J Am Coll Cardiol (2003) 2.36

Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. Eur Heart J (2013) 2.27

The Swedish Web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies (SWEDEHEART). Heart (2010) 2.24

Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J (2009) 2.23

Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J (2011) 2.21

Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation (2012) 2.18

Outcomes 1 year after thrombus aspiration for myocardial infarction. N Engl J Med (2014) 2.17

Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data. J Am Coll Cardiol (2010) 2.17

Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study. Eur Heart J (2012) 2.16

Prevalence and clinical outcomes of undiagnosed diabetes mellitus and prediabetes among patients with high-risk non-ST-segment elevation acute coronary syndrome. Am Heart J (2013) 2.14

Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes. Ann Intern Med (2007) 2.14

Improved but still high short- and long-term mortality rates after myocardial infarction in patients with diabetes mellitus: a time-trend report from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admission. Heart (2007) 2.05

Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation (2013) 2.03

Age, clinical presentation, and outcome of acute coronary syndromes in the Euroheart acute coronary syndrome survey. Eur Heart J (2006) 2.00

Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol (2010) 2.00

Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol (2012) 1.99

Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials. Stroke (2013) 1.99

Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J (2011) 1.98

Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation (2010) 1.96

Meeting report ESC forum on drug eluting stents, European Heart House, Nice, 27-28 September 2007. EuroIntervention (2009) 1.94

Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol (2007) 1.93

Influence of renal function on the effects of early revascularization in non-ST-elevation myocardial infarction: data from the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART). Circulation (2009) 1.93

Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Circulation (2012) 1.91

Transcatheter implantation of the MONARC coronary sinus device for mitral regurgitation: 1-year results from the EVOLUTION phase I study (Clinical Evaluation of the Edwards Lifesciences Percutaneous Mitral Annuloplasty System for the Treatment of Mitral Regurgitation). JACC Cardiovasc Interv (2011) 1.88

Nationwide cohort study of risk of ischemic heart disease in patients with celiac disease. Circulation (2011) 1.85

Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. Circulation (2012) 1.84

Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J Am Coll Cardiol (2008) 1.83

Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation (2012) 1.83

Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. Lancet (2012) 1.83

Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J (2010) 1.82

Troponin T levels and risk of 30-day outcomes in patients with the acute coronary syndrome: prospective verification in the GUSTO-IV trial. Am J Med (2003) 1.81

Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation (2013) 1.77

Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy. J Am Coll Cardiol (2003) 1.75

Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol (2007) 1.75

Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ (2011) 1.74

Anticoagulants in heart disease: current status and perspectives. Eur Heart J (2007) 1.73

Prognostic value of biomarkers during and after non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol (2009) 1.71

Growth-differentiation factor-15 for early risk stratification in patients with acute chest pain. Eur Heart J (2008) 1.70

Pre-hospital thrombolysis delivered by paramedics is associated with reduced time delay and mortality in ambulance-transported real-life patients with ST-elevation myocardial infarction. Eur Heart J (2006) 1.70

Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation. Circulation (2010) 1.68

Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation (2004) 1.67

Improved adherence to Swedish national guidelines for acute myocardial infarction: the Quality Improvement in Coronary Care (QUICC) study. Am Heart J (2006) 1.66

Digoxin and mortality in atrial fibrillation: a prospective cohort study. Eur J Clin Pharmacol (2007) 1.66